AM Press ReleasesBiomaterialsBioprinting

Aprecia Pharmaceuticals and Cycle Pharmaceuticals partner to develop 3D printed orphan drugs

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Aprecia Pharmaceuticals,  a company specializing in the 3D printing of pharmaceuticals, and Cycle Pharmaceuticals, signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose Technology platform. ZipDose is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration.

“Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s ZipDose 3DP technology can formulate fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market. As such, this advanced technology can uniquely overcome both pill burden and dysphagia – swallowing difficulties – both of which are life-long, daily issues for so many rare disease patients.” Antonio Benedetti, CEO of Cycle.

Aprecia expects to use its ZipDose Technology to transform the way people take medicine. Its first innovation, ZipDose Technology can be combined with a wide variety of active pharmaceutical ingredients to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Aprecia is committed to enhancing the patient experience through novel approaches to drug delivery that address unmet treatment needs to eliminate patient suffering and caregiver burden.

“We are excited to work with the Cycle team, and we see important synergies in the companies’ shared mission to address unmet needs in patient care,” said Don Wetherhold, CEO of Aprecia. “Cycle specializes in orphan drugs – they have proven that they can deliver quality-of-life improvements to rare disease patients around the world. Aprecia is fully committed to applying its ZipDose 3DP printing technology to address real-world, daily issues faced by rare disease patients,” he continued.

Cycle Pharmaceuticals is a Cambridge-based pharmaceutical company that optimizes and increases access to existing pharmaceuticals. Specifically, Cycle focuses on three areas of pharmaceutical development: improving orphan drugs, which treat the under-served rare disease patient community; reinstating drug products that have been previously marketed; working with our academic and other partners to extend pharmaceuticals to new medical areas where there is clear unmet need.

Research
Consumer Products AM 2024

This new market study from VoxelMatters provides an in-depth analysis and forecast of polymer and metal AM in the consumer products industry across the three core segments of the additive manufactu...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.